Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 977 of 6351
-
New drug combo before liver surgery shows promise in early trial
Disease control OngoingThis phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
One-Week radiation may cut lymphedema risk in breast cancer patients
Disease control OngoingThe primary objective of this study is to determine if hypofractionated RT delivered over 1 week to the breast or chest wall and regional nodes (26Gy in 5 daily fractions) following BCS or mastectomy, is non-inferior to conventional fractionation to the breast or chest wall and r…
Phase 3 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo approach aims to tame transplant complications in bone marrow cancer
Disease control Recruiting nowThis initial cohort of this phase II trial studied the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical (Haplo) transplantation for the treatment of primary or secondary myelofibrosis (MF). The primary risk of using Haplo HCT in patients with MF is graf…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients wi…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for older leukemia patients with gentler drug combo
Disease control OngoingThe Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727 when given in combination with venetoclax for the treatment of newly diagnosed acute m…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Blood test could spot hidden breast cancer early and guide Life-Saving treatment
Disease control OngoingA randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Phase 2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a ketamine shot stop suicidal thoughts in minutes?
Symptom relief PausedRising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide. There is no approved treatment for rapid relief of suicidal thoughts although clinica…
Phase 4 • Sponsor: New York State Psychiatric Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Gene-Corrected skin cells may offer lasting relief for 'Butterfly Children'
Disease control By invitation onlyA Long-Term Extension Study for Participants Previously Treated with EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
The eyes may hold a window to brain health: a trial tests a new marker and treatment
Disease control Recruiting nowCerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactiv…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for AML patients: experimental vaccine-like therapy aims to prevent relapse
Disease control OngoingTo assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second or later complete remission (CR2) or second or later complete rem…
Phase 3 • Sponsor: Sellas Life Sciences Group • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can a single drug shrink nasal polyps and restore breathing?
Disease control CompletedThis is a randomized, double blind, placebo controlled, parallel group phase III study designed to assess the clinical efficacy and safety of 100 milligrams (mg) subcutaneous (SC) mepolizumab treatment in adults with CRSwNP/ECRS for the purpose of registration in Japan and China.…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo shows promise against hard-to-treat breast cancer
Disease control CompletedThis study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 a…
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy shows promise for Tough-to-Treat liver cancer
Disease control CompletedThe purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a vaccine protect the most vulnerable? a study probes immune response in transplant patients
Knowledge-focused Stopped earlyThe investigators goal is to assess the vaccine response of kidney transplant patients following vaccination against SARS-CoV-2. The study population will be derived from cohorts of kidney transplant patients who have been transplanted for more than 3 months and have no contrain…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat multiple myeloma
Disease control OngoingThe purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressin…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinu…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New blood thinner aims to cut bleeding risk in AF patients
Disease control OngoingThe purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Phase 2 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Urine-derived stem cell therapy shows promise for reducing surgery complications in boys with hypospadias
Disease control CompletedHypospadias is one of the common congenital malformation disorders in male children, with a ratio of about 1 to 300 in newborn boys. Proximal hypospadias, due to the underdeveloped corpus spongiosum, has a high incidence of postoperative complications (e.g., urethral fistula, str…
Sponsor: Shanghai Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Higher dose of schistosomiasis drug shows promise for toddlers
Disease control CompletedThe overall goals of this proposal are to conduct a trial to address the significant gaps with respect to our understanding of best approaches to treatment of children ages 1-4 with intestinal schistosomiasis. Over 200 million individuals worldwide are infected with one of three …
Phase 2 • Sponsor: Rhode Island Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody drug shows promise for Hard-to-Treat myeloma
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC